

**TRISTEL plc**  
**("Tristel" or the "Company")**

**VISICLEAN™ Product Launch**

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces the launch of its new ultrasound probe decontamination product, Tristel VISICLEAN™, the first detergent of its kind with colour technology, enabling visible coverage and confirmation of high level disinfection.

Tristel VISICLEAN™ is deployed on the ultrasound probe, dyeing it pink, and when exposed to Tristel CIO via Tristel DUO ULT™, the pink dye disappears, visibly verifying that the probe has been high level disinfected. Tristel VISICLEAN™ is now available within the VISI Combination Pack, a convenient, all-in-one solution for ultrasound probe decontamination. Effective high-level disinfection begins with cleaning, which eliminates organic matter and reduces microbes to ensure proper sterilisation. This is performed manually and must be done each time. Tristel VISICLEAN™ is the only cleaning solution with visible verification, ensuring full auditability and compliance with protocols.



***Tristel VISICLEAN™, DUO ULT™ and DRY WIPES™, the products within the VISI Combination Pack***

The VISI Combination Pack includes the Company's new product, Tristel VISICLEAN™, along with two pre-existing products, Tristel DUO ULT™ & Tristel DRY WIPES™. Together, these products enable clinicians to perform manual decontamination procedures with confidence, precision, and audit-ready traceability via Tristel's 3T™ digital platform. VISI Combination Packs are now available to healthcare providers across the UK and are being launched globally on a phased basis, as and when the Company secures the necessary local regulatory clearances.

Tristel's proprietary chlorine dioxide chemistry is globally trusted for its broad-spectrum efficacy and resistance-proof mechanism. With over 30 years of experience in high-level disinfection, Tristel continues to remain at the forefront of infection prevention.

**Matt Sassone, CEO of Tristel plc, said:** *"We are pleased to launch Tristel VISICLEAN™, as part of the VISI Combination Pack, delivering visible cleaning, confirmed disinfection, and digital traceability, all in one intuitive kit. The scope for these products is vast and the up-sell opportunity from Tristel DUO ULT™ alone would result in 14 million cleaning procedures per annum."*

**For further information please contact:**

**Tristel plc**  
Matt Sassone, Chief Executive Officer  
Anna Wasyl, Chief Financial Officer

Via Walbrook PR  
[www.investors.tristel.com](http://www.investors.tristel.com)

**Walbrook PR Ltd**  
Paul McManus / Lianne Applegarth / Anna Dunphy

Tel: 020 7933 8780 or [tristel@walbrookpr.com](mailto:tristel@walbrookpr.com)  
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

**Cavendish Capital Markets Ltd**  
Geoff Nash / Callum Davidson/Trisya Jamaludin (Corporate Finance)  
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

Tel: 020 7220 0500





#### **About Tristel plc**

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO<sub>2</sub>) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the [Tristel](#) brand, and under the [Cache](#) brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets double digit revenue growth annually and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <https://tristel.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

PRLFZLFLEKLZBBK